Gene

FANCC

FA complementation group C

Explore in graph →CI-GENE-00001607HGNC:3584 ENSG00000158169 NCBI 2176 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
FANCC Loss-of-function1
Chlorambucil + Cisplatin + Gemcitabine + Melphalan + MitomycinSubstitutes	Malignant Pancreatic Neoplasm	Predictive	D	Supports Sensitivity Response	3	accepted	EID1307 In the pancreatic cell lines PL11 (FANCC homozygous deletion) and Hs766T (FANCG-mutated), sensitivity to DNA cross-linking agents was observed. PL11 cells (empty vector transduced) were more sensitive… (full text at CIViC) PMID 16243825 · van der Heijden et al., 2005 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (25)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved25 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Disparities in metastatic colorectal cancer between Africans and Americans (MSK, 2020) crc_nigerian_2020	Colorectal Adenocarcinoma	Ssm

Literature

Linked publications (1)

25 per page, newest first.

pubmedPublishedShowing 1–1 of 1 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.
· Clin Cancer Res · 2005 · PMID 16243825 · validated civic_curation pubmed